AstraZeneca CEO Pascal Soriot said AI is helping the company develop medicines faster and make smarter decisions throughout the research process.

At ASCO 2026, AstraZeneca unveiled initial clinical data for AZD-3470 in relapsed/refractory classical Hodgkin lymphoma.

AstraZeneca ((AZN)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...

AstraZeneca Plc AZN on Monday reported Phase 3 EMERALD-3 trial results showing that its immunotherapy-based STRIDE regimen, ...

Evinova today announced strategic collaborations with global life sciences companies Astellas Pharma Inc. ("Astellas"), AstraZeneca and Bristol Myers Squibb to accelerate their global clinical ...

The drug being developed by TYK Medicines targets lung cancer that has spread to the brain, where market competition is already fierce The market leader in lung cancer drugs, AstraZeneca, declined to ...

The FDA real-time clinical trial model enables prospective safety monitoring, improving risk assessment and speeding oncology drug development.

(RTTNews) - Arcus Biosciences, Inc. (RCUS), Wednesday announced a clinical trial collaboration agreement with AstraZeneca (AZN) to evaluate casdatifan in combination with volrustomig for the treatment ...

On Tuesday, Merck & Co Inc (NYSE:MRK) shared topline results from its Phase 2b/3 clinical trial (MK-1654-004) of clesrovimab (MK-1654). Clesrovimab is the company’s investigational prophylactic ...